Press release summary
Alpha Teknova and Pluristyx said Oct. 2 that Pluristyx is completing a Type II Drug Master File for the PluriFreeze cryopreservation system for submission to the U.S. Food and Drug Administration. The filing is intended to support advanced-therapy developers that use the system during preclinical work and later incorporate it into clinical development or manufacturing.
Developers may request a letter of authorization allowing the FDA to reference confidential chemistry, manufacturing and controls information in an Investigational New Drug application or Biologics License Application. PluriFreeze combines a protective cellular wash with a low-viscosity freezing medium containing 10% dimethyl sulfoxide. The companies say the synthetic, animal-origin-free system is available for research and good manufacturing practice applications. Teknova manufactures and distributes the products in the United States and Canada.
Why it matters for laboratories
A Drug Master File can reduce repetitive documentation work when cell-therapy developers move a cryopreservation process from research into regulated manufacturing. It does not represent FDA approval of the product or a therapy. Process-development and quality laboratories should still evaluate cell recovery, viability, comparability, sterility, storage stability and material compatibility for their own cell types and workflows before adoption.
Original source: Teknova announcement.






Leave a Reply